Skip to Content

Press Releases and Events

PRESS RELEASES


Press Release | June 30, 2025

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

READ MORE

Press Release | June 16, 2025

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

READ MORE

Press Release | June 10, 2025

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE

Press Release | May 23, 2025

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

READ MORE

Press Release | May 15, 2025

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

READ MORE

Press Release | May 12, 2025

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE

Press Release | May 8, 2025

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

READ MORE

Press Release | April 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE

Press Release | March 27, 2025

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

READ MORE

Press Release | March 10, 2025

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE

4 / 24